FL facts Flashcards
(24 cards)
Immunophenotype FL
CD19, CD20, CD10 positive
Translocation FL
t(14,18) IgH-bcl2
FLIPI
age > 60
Hb <12
LDH >ULN
Stage III/IV
> 4 lymph node areas
Median age FL
65
BMB involvmment in FL
70%
m7 FLIPI
Includes 7 gene mutations in addition to FLIPI- better prognostic ability
Stage I/II FL %
~ 10%
Radiation dose for stage I/II FL
24 Gy
Obino vs rituxi for FL
GALIUM study
CHOP, CVP, benda - backbone
Anti CD20 also given as maintenance
Obino had better PFS with no OS benefit
7 year PFS 63% vs 55%
R main in FL
PRIMA
Phase III
vs observation
Better PFS but not OS
More toxicities
Median PFS of 10 year
Backbone was R CHOP R CVP or FCM
Not BR
Tazemetostat for FL
EZH2 inhibitor
Phase II
FDA approved in 3rd line FL
not very toxic
Axi cell in FL
ZUMA5
3rd line
phase 2
(included also MZL)
ORR 94%
CR 77%
ZUMA 22
2nd line in POD24 or 3rd line
ongoing
Tisa cell in FL
ELARA trial
3rd line, phase 2
ORR 86%
CR 70%
Bridging Tx was allowed
R2 in RR FL
AUGMENT
RR FL
vs R
12 cycles
Superior PFS and OS
Median PFS of 40 months
Mosenutuzumab in FL
Bispecific Ab CD20-CD3
Phase II
3rd line
ORR 80%
CR 60%
ICANS/CRS G3 1/2%
8 cycles. 17 if not in CR.
3rd line
R vs W&W in low burden FL
ARDESHNA trial
R improves PFS
no OS
15-20% in W&W never needed Tx (10 years)
Median time to Tx in W&W- 2.5 years
BR vs RCHOP in FL
STiL
better PFS
BRIGHT
same PFS
both with less toxicity
R2 in ND FL
RELEVANCE
compared to R-chemo
non inferior
R2-Mosu vs R2 in RR FL
CELSTIMO
results pending
FLIPI2 vs FLIPI
FLIPI2 has BM, node > 6 cm, b2mg
FLIPI has Stage IV, lymph nodes>4, LDH
Both have age>60, Hb<12
M7-FLIPI
FLIPI + 7 genes
R effect on transformation rate in FL
Reduces
2nd line Tx in FL
R^2
R-CHOP
No need for ASCT as consolidation
Subtypes of indolent included in STiL study
FL
MZL
WM
MCL
